keyword
MENU ▼
Read by QxMD icon Read
search

Type 3 diabetes AD

keyword
https://www.readbyqxmd.com/read/29110972/patient-reported-outcomes-in-patients-with-type-2-diabetes-treated-with-dulaglutide-added-to-titrated-insulin-glargine-award-9
#1
Maria Yu, Kate Van Brunt, Zvonko Milicevic, Oralee Varnado, Kristina S Boye
PURPOSE: This 28-week, randomized, double-blind study compared a once-weekly injection of dulaglutide 1.5 mg to placebo, both added to titrated once-daily insulin glargine (with or without metformin), in patients with type 2 diabetes mellitus and inadequate glycemia control (control defined as hemoglobin A1c, ≥7% and ≤10.5%). Patient-reported outcomes were assessed as an exploratory objective to further understand patients' physical, psychological, and social aspects of well-being and injection-device experience...
October 27, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/29103664/canagliflozin-in-conjunction-with-sulfonylurea-maintains-glycemic-control-and-weight-loss-over-52-weeks-a-randomized-controlled-trial-in-patients-with-type-2-diabetes-mellitus
#2
Jean-François Yale, John Xie, Stephen E Sherman, Claude Garceau
PURPOSE: Our aim was to investigate the long-term efficacy and safety of canagliflozin, a sodium-glucose co-transporter 2 inhibitor, added to background sulfonylurea (SU) monotherapy for patients with type 2 diabetes mellitus. METHODS: The CANagliflozin cardioVascularAssessment Study (CANVAS) was a double-blind, placebo-controlled cardiovascular outcomes study that randomly assigned participants to receive placebo or canagliflozin 100 or 300 mg once daily in addition to routine therapy...
November 2, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/29097375/engineering-glucose-responsiveness-into-insulin
#3
Niels C Kaarsholm, Songnian Lin, Lin Yan, Theresa Kelly, Margaret van Heek, James Mu, Margaret Wu, Ge Dai, Yan Cui, Yonghua Zhu, Ester Carballo-Jane, Vijay Reddy, Peter Zafian, Pei Huo, Shuai Shi, Valentyn Antochshuk, Aimie Ogawa, Franklin Liu, Sandra C Souza, Wolfgang Seghezzi, Joseph Duffy, Mark Erion, Ravi Nargund, David E Kelley
Insulin has a narrow therapeutic index, reflected in a small margin between a dose that achieves good glycemic control and one that causes hypoglycemia. Once injected, the clearance of exogenous insulin is agnostic to blood glucose, aggravating the potential to cause hypoglycemia. We sought to create a "smart" insulin, one that can alter insulin clearance and hence insulin action in response to blood glucose, mitigating risk for hypoglycemia. The approach added saccharide units to insulin, to create insulin analogs with affinity for both the insulin receptor (IR) and mannose receptor C-type 1 (MR), which functions to clear endogenous mannosylated proteins, a principle used to endow insulin analogs with glucose responsivity...
November 2, 2017: Diabetes
https://www.readbyqxmd.com/read/29066573/incidence-prevalence-and-seasonal-onset-variation-of-addison-s-disease-among-persons-with-type-1-diabetes-mellitus-nationwide-matched-cohort-studies
#4
Dimitrios Chantzichristos, Anders Persson, Björn Eliasson, Mervete Miftaraj, Stefan Franzén, Ann-Marie Svensson, Gudmundur Johannsson
OBJECTIVES: We determined the incidence and prevalence of Addison's disease (AD) among persons with or without type 1 diabetes mellitus (T1DM) in nationwide, matched cohort studies. METHODS: Persons with T1DM were identified from the Swedish National Diabetes Register and each was matched for age, sex, year, and county to five controls randomly selected from the general population. Persons with AD were identified from the Swedish National Inpatient Register. Baseline demographics and seasonal onset variation of AD were presented by descriptive statistics...
October 24, 2017: European Journal of Endocrinology
https://www.readbyqxmd.com/read/29053202/treatment-satisfaction-with-itca-650-a-novel-drug-device-delivering-continuous-exenatide-versus-twice-daily-injections-of-exenatide-in-type-2-diabetics-on-metformin
#5
Robert Henry, Julio Rosenstock, John F McCarthy, Ginger Carls, Tom Alessi, John Yee, Michelle Baron
AIMS: To evaluate treatment satisfaction in patients with type 2 diabetes (T2D), not adequately controlled by metformin, randomized to ITCA 650 (continuous exenatide in osmotic mini-pump) versus twice-daily exenatide injections (Ex-BID). MATERIALS AND METHODS: The Diabetes Medication Satisfaction Tool (DM-SAT) was administered and assessments made at baseline, week 8, and week 20 in a 24 week open-label phase 2 trial. In Stage I (weeks 1-12), 155 patients, comprising the ITT population, were randomized to three groups: ITCA 650 20 μg/day, ITCA 650 40 μg/day and Ex-BID 10 μg BID...
October 20, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29036825/the-emergence-of-a-new-conceptual-framework-for-alzheimer-s-disease
#6
Dubois Bruno
The New Criteria for the diagnosis of Alzheimer's disease (AD), published by a group of experts in 2007, have resulted in a revolution in the comprehension of the disease. Before 2007, the diagnosis of AD dementia was done through a process of exclusion: it was considered in the case of patients with a dementia syndrome without identified etiologies. This traditional algorithm had three major limitations that penalize the disease: 1) a low accuracy of the performance which may share responsibility for negative results in clinical trials; 2) a late identification of the patients only when they reach the threshold of dementia which may delay the activation of optimal care; and last but not least, 3) an absence of clear recognition of AD as a disease because of the lack of specific arguments for its identification...
October 7, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28986504/causes-of-death-in-a-contemporary-cohort-of-patients-with-type-2-diabetes-and-atherosclerotic-cardiovascular-disease-insights-from-the-tecos-trial
#7
Abhinav Sharma, Jennifer B Green, Allison Dunning, Yuliya Lokhnygina, Sana M Al-Khatib, Renato D Lopes, John B Buse, John M Lachin, Frans Van de Werf, Paul W Armstrong, Keith D Kaufman, Eberhard Standl, Juliana C N Chan, Larry A Distiller, Russell Scott, Eric D Peterson, Rury R Holman
OBJECTIVE: We evaluated the specific causes of death and their associated risk factors in a contemporary cohort of patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD). RESEARCH DESIGN AND METHODS: We used data from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) study (n = 14,671), a cardiovascular (CV) safety trial adding sitagliptin versus placebo to usual care in patients with type 2 diabetes and ASCVD (median follow-up 3 years)...
October 6, 2017: Diabetes Care
https://www.readbyqxmd.com/read/28965829/reduced-brain-insulin-signaling-a-seminal-process-in-alzheimer-s-disease-pathogenesis
#8
REVIEW
George S Bloom, John S Lazo, Andrés Norambuena
The synaptic dysfunction and death of neurons that mediate memory and cognition account together for the behavioral symptoms of Alzheimer's disease (AD). Reduced insulin signaling in the brain is a hallmark of AD patients, even in the absence of systemic type 1 or type 2 diabetes, prompting some researchers to refer to AD as brain-specific, or type 3 diabetes. A key question that arises about this signature feature of AD is "how, if at all, does the brain's impaired ability to utilize insulin contribute to the behavioral deficits associated with AD?" The fact that type 2 diabetes is a risk factor for AD suggests a causative role for impaired insulin responsiveness in AD pathogenesis, but how that might occur at a detailed molecular level had been elusive...
September 29, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/28936587/metabolite-ratios-as-potential-biomarkers-for-type-2-diabetes-a-direct-study
#9
Sophie Molnos, Simone Wahl, Mark Haid, E Marelise W Eekhoff, René Pool, Anna Floegel, Joris Deelen, Daniela Much, Cornelia Prehn, Michaela Breier, Harmen H Draisma, Nienke van Leeuwen, Annemarie M C Simonis-Bik, Anna Jonsson, Gonneke Willemsen, Wolfgang Bernigau, Rui Wang-Sattler, Karsten Suhre, Annette Peters, Barbara Thorand, Christian Herder, Wolfgang Rathmann, Michael Roden, Christian Gieger, Mark H H Kramer, Diana van Heemst, Helle K Pedersen, Valborg Gudmundsdottir, Matthias B Schulze, Tobias Pischon, Eco J C de Geus, Heiner Boeing, Dorret I Boomsma, Anette G Ziegler, P Eline Slagboom, Sandra Hummel, Marian Beekman, Harald Grallert, Søren Brunak, Mark I McCarthy, Ramneek Gupta, Ewan R Pearson, Jerzy Adamski, Leen M 't Hart
AIMS/HYPOTHESIS: Circulating metabolites have been shown to reflect metabolic changes during the development of type 2 diabetes. In this study we examined the association of metabolite levels and pairwise metabolite ratios with insulin responses after glucose, glucagon-like peptide-1 (GLP-1) and arginine stimulation. We then investigated if the identified metabolite ratios were associated with measures of OGTT-derived beta cell function and with prevalent and incident type 2 diabetes...
September 21, 2017: Diabetologia
https://www.readbyqxmd.com/read/28923815/use-of-complementary-health-approaches-among-diverse-primary-care-patients-with-type-2-diabetes-and-association-with-cardiometabolic-outcomes-from-the-sf-bay-collaborative-research-network-sf-bay-crn
#10
Margaret A Handley, Judy Quan, Maria T Chao, Neda Ratanawongsa, Urmimala Sarkar, Sophia Emmons-Bell, Dean Schillinger
PURPOSE: To describe use of complementary health approaches (CHAs) among patients with type 2 diabetes, and independent associations between CHA use and Hemoglobin A1c (A1C) and lower-density lipoprotein (LDL) cholesterol. METHODS: Participants were enrolled onto the SMARTSteps Program, a diabetes self-management support program conducted between 2009 and 2013 in San Francisco. At the 6-month interview, CHA use in the prior 30 days was estimated using a 12-item validated instrument...
September 2017: Journal of the American Board of Family Medicine: JABFM
https://www.readbyqxmd.com/read/28921862/efficacy-and-safety-of-the-addition-of-ertugliflozin-in-patients-with-type-2-diabetes-mellitus-inadequately-controlled-with-metformin-and-sitagliptin-the-vertis-sita2-placebo-controlled-randomized-study
#11
Samuel Dagogo-Jack, Jie Liu, Roy Eldor, Guillermo Amorin, Jeremy Johnson, Darcy Hille, Yuqin Liao, Susan Huyck, Gregory Golm, Steven G Terra, James P Mancuso, Samuel S Engel, Brett Lauring
AIMS: To assess ertugliflozin in patients with type 2 diabetes who are inadequately controlled by metformin and sitagliptin. MATERIALS AND METHODS: In this double-blind randomized study (Clinicaltrials.gov NCT02036515), patients (glycated haemoglobin [HbA1c] 7.0% to 10.5% [53-91 mmol/mol] receiving metformin ≥1500 mg/d and sitagliptin 100 mg/d; estimated glomerular filtration rate [eGFR] ≥60 mL/min/1.73 m(2) ) were randomized to ertugliflozin 5 mg once-daily, 15 mg once-daily or placebo...
September 17, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28917545/effects-of-acarbose-on-cardiovascular-and-diabetes-outcomes-in-patients-with-coronary-heart-disease-and-impaired-glucose-tolerance-ace-a-randomised-double-blind-placebo-controlled-trial
#12
Rury R Holman, Ruth L Coleman, Juliana C N Chan, Jean-Louis Chiasson, Huimei Feng, Junbo Ge, Hertzel C Gerstein, Richard Gray, Yong Huo, Zhihui Lang, John J McMurray, Lars Rydén, Stefan Schröder, Yihong Sun, Michael J Theodorakis, Michal Tendera, Lynne Tucker, Jaakko Tuomilehto, Yidong Wei, Wenying Yang, Duolao Wang, Dayi Hu, Changyu Pan
BACKGROUND: The effect of the α-glucosidase inhibitor acarbose on cardiovascular outcomes in patients with coronary heart disease and impaired glucose tolerance is unknown. We aimed to assess whether acarbose could reduce the frequency of cardiovascular events in Chinese patients with established coronary heart disease and impaired glucose tolerance, and whether the incidence of type 2 diabetes could be reduced. METHODS: The Acarbose Cardiovascular Evaluation (ACE) trial was a randomised, double-blind, placebo-controlled, phase 4 trial, with patients recruited from 176 hospital outpatient clinics in China...
November 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28910237/effects-of-once-weekly-exenatide-on-cardiovascular-outcomes-in-type-2-diabetes
#13
RANDOMIZED CONTROLLED TRIAL
Rury R Holman, M Angelyn Bethel, Robert J Mentz, Vivian P Thompson, Yuliya Lokhnygina, John B Buse, Juliana C Chan, Jasmine Choi, Stephanie M Gustavson, Nayyar Iqbal, Aldo P Maggioni, Steven P Marso, Peter Öhman, Neha J Pagidipati, Neil Poulter, Ambady Ramachandran, Bernard Zinman, Adrian F Hernandez
BACKGROUND: The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. METHODS: We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly. The primary composite outcome was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke...
September 28, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28904527/cost-effectiveness-of-vildagliptin-versus-glimepiride-as-add-on-treatment-to-metformin-for-the-treatment-of-diabetes-mellitus-type-2-patients-in-greece
#14
Hara Kousoulakou, Magdalini Hatzikou, Varvara Baroutsou, John Yfantopoulos
OBJECTIVES: This study was designed to assess the cost-effectiveness of vildagliptin versus glimepiride as add-on to metformin in the management of type 2 diabetes mellitus (T2DM) patients in the Greek healthcare setting. METHODS: A cost-effectiveness model was designed, using MS Excel, to compare two treatment strategies. Strategy 1 consisted of first-line metformin, followed by metformin + vildagliptin in second-line, while strategy 2 consisted of first line metformin, followed by metformin + glimepiride in second line...
2017: Cost Effectiveness and Resource Allocation: C/E
https://www.readbyqxmd.com/read/28899222/effects-of-sotagliflozin-added-to-insulin-in-patients-with-type-1-diabetes
#15
Satish K Garg, Robert R Henry, Phillip Banks, John B Buse, Melanie J Davies, Gregory R Fulcher, Paolo Pozzilli, Diane Gesty-Palmer, Pablo Lapuerta, Rafael Simó, Thomas Danne, Darren K McGuire, Jake A Kushner, Anne Peters, Paul Strumph
Background In most patients with type 1 diabetes, adequate glycemic control is not achieved with insulin therapy alone. We evaluated the safety and efficacy of sotagliflozin, an oral inhibitor of sodium-glucose cotransporters 1 and 2, in combination with insulin treatment in patients with type 1 diabetes. Methods In this phase 3, double-blind trial, which was conducted at 133 centers worldwide, we randomly assigned 1402 patients with type 1 diabetes who were receiving treatment with any insulin therapy (pump or injections) to receive sotagliflozin (400 mg per day) or placebo for 24 weeks...
September 13, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28877915/plasma-concentrations-of-afamin-are-associated-with-prevalent-and-incident-type-2-diabetes-a-pooled-analysis-in-more-than-20-000-individuals
#16
Barbara Kollerits, Claudia Lamina, Cornelia Huth, Pedro Marques-Vidal, Stefan Kiechl, Ilkka Seppälä, Jackie Cooper, Steven C Hunt, Christa Meisinger, Christian Herder, Ludmilla Kedenko, Johann Willeit, Barbara Thorand, Doreen Dähnhardt, Doris Stöckl, Karin Willeit, Michael Roden, Wolfgang Rathmann, Bernhard Paulweber, Annette Peters, Mika Kähönen, Terho Lehtimäki, Olli T Raitakari, Steve E Humphries, Peter Vollenweider, Hans Dieplinger, Florian Kronenberg
OBJECTIVE: The human vitamin E-binding glycoprotein afamin is primarily expressed in the liver and has been associated with prevalent and incident metabolic syndrome. These data were in line with observations in transgenic mice. We thus investigated whether afamin concentrations are associated with prediabetes, type 2 diabetes, and insulin resistance (IR). RESEARCH DESIGN AND METHODS: Individual-level baseline (n = 20,136) and follow-up data (n = 14,017) of eight prospective cohort studies were investigated...
September 6, 2017: Diabetes Care
https://www.readbyqxmd.com/read/28870582/linking-alzheimer-s-disease-and-type-2-diabetes-novel-shared-susceptibility-genes-detected-by-cfdr-approach
#17
Xia-Fang Wang, Xu Lin, Ding-You Li, Rou Zhou, Jonathan Greenbaum, Yuan-Cheng Chen, Chun-Ping Zeng, Lin-Ping Peng, Ke-Hao Wu, Zeng-Xin Ao, Jun-Min Lu, Yan-Fang Guo, Jie Shen, Hong-Wen Deng
BACKGROUND: Both type 2 diabetes (T2D) and Alzheimer's disease (AD) occur commonly in the aging populations and T2D has been considered as an important risk factor for AD. The heritability of both diseases is estimated to be over 50%. However, common pleiotropic single-nucleotide polymorphisms (SNPs)/loci have not been well-defined. The aim of this study is to analyze two large public accessible GWAS datasets to identify novel common genetic loci for T2D and/or AD. METHODS AND MATERIALS: The recently developed novel conditional false discovery rate (cFDR) approach was used to analyze the summary GWAS datasets from International Genomics of Alzheimer's Project (IGAP) and Diabetes Genetics Replication And Meta-analysis (DIAGRAM) to identify novel susceptibility genes for AD and T2D...
September 15, 2017: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/28868826/determinants-of-long-term-durable-glycemic-control-in-new-onset-type-2-diabetes-mellitus
#18
Kyoung Jin Kim, Ju Hee Choi, Kyeong Jin Kim, Jee Hyun An, Hee Young Kim, Sin Gon Kim, Nam Hoon Kim
BACKGROUND: Long-term durable glycemic control is a difficult goal in the management of type 2 diabetes mellitus (T2DM). We evaluated the factors associated with durable glycemic control in a real clinical setting. METHODS: We retrospectively reviewed the medical records of 194 new-onset, drug-naïve patients with T2DM who were diagnosed between January 2011 and March 2013, and were followed up for >2 years. Glycemic durability was defined as the maintenance of optimal glycemic control (glycosylated hemoglobin [HbA1c] <7...
August 2017: Diabetes & Metabolism Journal
https://www.readbyqxmd.com/read/28857451/effect-of-ertugliflozin-on-glucose-control-body-weight-blood-pressure-and-bone-density-in-type-2-diabetes-mellitus-inadequately-controlled-on-metformin-monotherapy-vertis-met
#19
Julio Rosenstock, Juan Frias, Dénes Páll, Bernard Charbonnel, Raluca Pascu, Didier Saur, Amanda Darekar, Susan Huyck, Harry Shi, Brett Lauring, Steven G Terra
AIM: We evaluated the efficacy and safety of ertugliflozin, an SGLT2 inhibitor, in type 2 diabetes mellitus (T2DM) inadequately controlled (HbA1c, 7.0%-10.5%) with metformin monotherapy (≥1500 mg/d for ≥8 weeks). METHODS: This was a double-blind, 26-week, multicentre study with ongoing 78-week extension (ClinicalTrials.gov identifier: NCT02033889). A total of 621 participants were randomized 1:1:1 to placebo, or ertugliflozin 5 or 15 mg/d. The primary endpoint was change from baseline at week 26 in HbA1c...
August 31, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28855239/closed-loop-control-during-intense-prolonged-outdoor-exercise-in-adolescents-with-type-1-diabetes-the-artificial-pancreas-ski-study
#20
Marc D Breton, Daniel R Cherñavvsky, Gregory P Forlenza, Mark D DeBoer, Jessica Robic, R Paul Wadwa, Laurel H Messer, Boris P Kovatchev, David M Maahs
OBJECTIVE: Intense exercise is a major challenge to the management of type 1 diabetes (T1D). Closed loop control (CLC) systems (artificial pancreas) improve glycemic control during limited intensity and short duration of physical activity (PA). However, CLC has not been tested during extended vigorous outdoor exercise common among adolescents. RESEARCH DESIGN AND METHODS: Skiing presents unique metabolic challenges: intense prolonged PA, cold, altitude, and stress/fear/excitement...
August 30, 2017: Diabetes Care
keyword
keyword
73409
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"